Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial

Lian R Gao, Yu Chen, Ning K Zhang, Xi L Yang, Hui L Liu, Zhi G Wang, Xiao Y Yan, Yu Wang, Zhi M Zhu, Tian C Li, Li H Wang, Hai Y Chen, Yun D Chen, Chao L Huang, Peng Qu, Chen Yao, Bin Wang, Guang H Chen, Zhong M Wang, Zhao Y Xu, Jing Bai, Di Lu, Yan H Shen, Feng Guo, Mu Y Liu, Yong Yang, Yan C Ding, Ye Yang, Hai T Tian, Qing A Ding, Li N Li, Xin C Yang, Xiang Hu, Lian R Gao, Yu Chen, Ning K Zhang, Xi L Yang, Hui L Liu, Zhi G Wang, Xiao Y Yan, Yu Wang, Zhi M Zhu, Tian C Li, Li H Wang, Hai Y Chen, Yun D Chen, Chao L Huang, Peng Qu, Chen Yao, Bin Wang, Guang H Chen, Zhong M Wang, Zhao Y Xu, Jing Bai, Di Lu, Yan H Shen, Feng Guo, Mu Y Liu, Yong Yang, Yan C Ding, Ye Yang, Hai T Tian, Qing A Ding, Li N Li, Xin C Yang, Xiang Hu

Abstract

Background: The use of adult stem cells is limited by the quality and quantity of host stem cells. It has been demonstrated that Wharton's jelly-derived mesenchymal stem cells (WJMSCs), a primitive stromal population, could integrate into ischemic cardiac tissues and significantly improve heart function. In this randomized, controlled trial, our aim was to assess the safety and efficacy of intracoronary WJMSCs in patients with ST-elevation acute myocardial infarction (AMI).

Methods: In a multicenter trial, 116 patients with acute ST-elevation MI were randomly assigned to receive an intracoronary infusion of WJMSCs or placebo into the infarct artery at five to seven days after successful reperfusion therapy. The primary endpoint of safety: the incidence of adverse events (AEs) within 18 months, was monitored and quantified. The endpoint of efficacy: the absolute changes in myocardial viability and perfusion of the infarcted region from baseline to four months, global left ventricular ejection fraction (LVEF) from baseline to 18 months were measured using F-18-fluorodeoxyglucose positron emission computed tomography (F-18-FDG-PET) and 99mTc-sestamibi single-photon emission computed tomography (99mTc-SPECT), and two-dimensional echocardiography, respectively.

Results: During 18 months follow-up, AEs rates and laboratory tests including tumor, immune, and hematologic indexes were not different between the two groups. The absolute increase in the myocardial viability (PET) and perfusion within the infarcted territory (SPECT) was significantly greater in the WJMSC group [6.9 ± 0.6 % (95 %CI, 5.7 to 8.2)] and [7.1 ± 0.8 % (95 %CI, 5.4 to 8.8) than in the placebo group [3.3 ± 0.7 % (95 %CI, 1.8 to 4.7), P <0.0001] and 3.9 ± 0.6(95 %CI, 2.8 to 5.0), P = 0.002] at four months. The absolute increase in the LVEF at 18 months in the WJMSC group was significantly greater than that in the placebo group [7.8 ± 0.9 (6.0 to approximately 9.7) vs. 2.8 ± 1.2 (0.4 to approximately 5.1), P = 0.001]. Concomitantly, the absolute decreases in LV end-systolic volumes and end-diastolic volumes at 18 months in the WJMSC group were significantly greater than those in the placebo group (P = 0.0004, P = 0.004, respectively).

Conclusions: Intracoronary infusion of WJMSCs is safe and effective in patients with AMI, providing clinically relevant therapy within a favorable time window. This study encourages additional clinical trials to determine whether WJMSCs may serve as a novel alternative to BMSCs for cardiac stem cell-based therapy.

Trial registration: Clinical Trials NCT01291329 (02/05/2011).

Figures

Fig. 1
Fig. 1
Enrollment and outcomes
Fig. 2
Fig. 2
a Mean F-18-FDG-PET signal intensity in the infarct vessel area measured before and four months after transplantation. Comparison of mean F-18-FDG-PET signal intensity changes and absolute changes between the WJMSC group and the placebo group using analysis of covariance (ANCOVA). T-bars show the standard errors. b Mean signal intensity of 99mTc-MIBI perfusion imaging in the infarcted vessel area measured before and four months after transplantation. Comparison of mean 99mTc-MIBI signal intensity changes and absolute changes between the WJMSC group and the placebo group by ANCOVA. T-bars show the standard errors WJMSC Wharton’s jelly-derived mesenchymal stem cells
Fig. 3
Fig. 3
a Comparison of changes in the global left ventricular ejection fraction (LVEF) between the WJMSC group and the placebo group measured by two dimensional-echocardiograph before transplantation and at the 4-, 12- and 18-month follow-ups. b. The absolute changes in LVEF, LVESV and LVEDV between the WJMSC group and the placebo group at 18 months measured by ECG and analyzed by ANCOVA. T-bars show the standard errors ANCOVA analysis of covariance, ECG echocardiogram, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, WJMSC Wharton’s jelly-derived mesenchymal stem cells

References

    1. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362:2155–65. doi: 10.1056/NEJMoa0908610.
    1. Rosenzweig A. Cardiac regeneration. Science. 2012;338:1549–50. doi: 10.1126/science.1228951.
    1. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93–8. doi: 10.1161/hc0102.101442.
    1. Vela DC, Silva GV, Assad JA, Sousa AL, Coulter S, Fernandes MR, et al. Histopathological study of healing after allogenic mesenchymal stem cell delivery in myocardial infarction in dogs. J Histochem Cytochem. 2009;57:167–76. doi: 10.1369/jhc.2008.952507.
    1. Perin EC, Tian M, Marini FC, 3rd, Silva GV, Zheng Y, Baimbridge F, et al. Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model. PLoS One. 2011;6:e22949. doi: 10.1371/journal.pone.0022949.
    1. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923–40. doi: 10.1161/CIRCRESAHA.111.243147.
    1. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210–21. doi: 10.1056/NEJMoa060186.
    1. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113:1287–94. doi: 10.1161/CIRCULATIONAHA.105.575118.
    1. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92–5. doi: 10.1016/j.amjcard.2004.03.034.
    1. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–86. doi: 10.1016/j.jacc.2009.06.055.
    1. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters a systematic review and meta-analysis. Circulation. 2012;126:551–68. doi: 10.1161/CIRCULATIONAHA.111.086074.
    1. Gao LR, Pei XT, Ding QA, Chen Y, Zhang NK, Chen HY, et al. A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol. 2013;168:3191–9. doi: 10.1016/j.ijcard.2013.04.112.
    1. Fan M, Chen W, Liu W, Du GQ, Jiang SL, Tian WC, et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. 2010;13:429–38. doi: 10.1089/rej.2009.0986.
    1. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004;22:1330–7. doi: 10.1634/stemcells.2004-0013.
    1. Troyer DL, Weiss ML. Concise review: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008;26:591–9. doi: 10.1634/stemcells.2007-0439.
    1. Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells. 2007;25:319–31. doi: 10.1634/stemcells.2006-0286.
    1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013;14:11692–712. doi: 10.3390/ijms140611692.
    1. Gao LR, Zhang NK, Ding QA, Chen HY, Hu X, Jiang S, et al. Common expression of stemness molecular markers and early cardiac transcription factors in Wharton’s jelly-derived mesenchymal stem cells and hESCs. Cell Transplant. 2013;22:1883–900. doi: 10.3727/096368912X662444.
    1. Nartprayut K, U-Pratya Y, Kheolamai P, Manochantr S, Chayosumrit M, Issaragrisil S, et al. Cardiomyocyte differentiation perinatally-derived mesenchymal stem cells. Mol Med Rep. 2013;7:1465–9.
    1. Lupu M, Khalil M, Andrei E, Iordache F, Pfannkuche K, Neef K, et al. Integration properties of Wharton’s jelly-derived novel mesenchymal stem cells into ventricular slices of murine hearts. Cell Physiol Biochem. 2011;28:63–76. doi: 10.1159/000331714.
    1. Zhang W, Liu XC, Yang L, Zhu DL, Zhang YD, Chen Y, et al. Wharton’s jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction. Coron Artery Dis. 2013;24:549–58. doi: 10.1097/MCA.0b013e3283640f00.
    1. Lopez Y, Lutjemeier B, Seshareddy K, Trevino EM, Hageman KS, Musch TI, et al. Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report. Curr Stem Cell Res Ther. 2013;8:46–59. doi: 10.2174/1574888X11308010007.
    1. Can A, Karahuseyinoglu S. Concise review: human cord stroma with regard to the source of fetus-derived stem cells. Stem Cells. 2007;25:2886–95. doi: 10.1634/stemcells.2007-0417.
    1. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Cells Stem Cells. 2008;26:2865–74. doi: 10.1634/stemcells.2007-1028.
    1. Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton’s jelly of the human umbilical cord. Stem Cell Rev Rep. 2013;9:226–40. doi: 10.1007/s12015-012-9418-z.
    1. Chen H, Zhang N, Li T, Guo J, Wang Z, Yang M, et al. Human umbilical cord Wharton’s jelly stem cells: immune property genes assay and effect of transplantation on the immune cells of heart failure patients. Cell Immunol. 2012;276:83–90. doi: 10.1016/j.cellimm.2012.03.012.
    1. Kushner FG, Hand M, Smith SC, Jr, King SB, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271–306. doi: 10.1161/CIRCULATIONAHA.109.192663.
    1. Gao LR, Wang ZG, Zhu ZM, Fei YX, He S, Tian HT, et al. Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2006;98:597–602. doi: 10.1016/j.amjcard.2006.03.034.
    1. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med. 2006;355:1730–5. doi: 10.1056/NEJMhpr063086.
    1. Gao LR, Zhang NK, Chen Y, Wang ZG, Zhu ZM, Yang Y. A dosing study of Wharton’s jelly-derived mesenchymal stem cell for intracoronary infusion in a pig model of acute coronary myocardial infarction. Navy Med J. 2011;3:21–8.
    1. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539–42. doi: 10.1161/hc0402.102975.
    1. Liu Q, Zhao S, Yan C, Lu M, Jiang S, Zhang Y, et al. Myocardial viability in chronic ischemic heart disease: comparison of delayed-enhancement magnetic resonance imaging with 99mTc-sestamibi and 18-F-fluorodeoxyglucose single-photon emission computed tomography. Nucl Med Commun. 2009;30:610–6. doi: 10.1097/MNM.0b013e32832b529e.
    1. Mylonas I, Beanlands RS. Radionuclide imaging of viable myocardium: is it under- utilized? Curr Cardiovasc Imaging Rep. 2011;4:251–61. doi: 10.1007/s12410-011-9074-8.
    1. Nekanti U, Rao VB, Bahirvani AG, Jan M, Totey S, Ta M. Long-term expansion and pluripotent marker array analysis of Wharton’s jelly-derived mesenchymal stem cells. Stem Cells Dev. 2010;19:117–30. doi: 10.1089/scd.2009.0177.
    1. Fong CY, Chak LL, Biswas A, Tan JH, Gauthaman K, Chan WK, et al. Human Wharton’s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev Rep. 2011;7:1–6. doi: 10.1007/s12015-010-9166-x.
    1. Sobolewski K, Malkowski A, Bankowski E, Jaworski S. Wharton’s jelly as a reservoir of peptide growth factors. Placenta. 2005;26:747–52. doi: 10.1016/j.placenta.2004.10.008.
    1. Fong CY, Richards M, Manasi N, Biswas A, Bongso A. Comparative growth behaviour and characterization of stem cells from human Wharton's jelly. Reprod Biomed Online. 2007;6:708–18. doi: 10.1016/S1472-6483(10)60539-1.

Source: PubMed

3
Abonneren